Back to top
more

Aquestive Therapeutics (AQST)

(Real Time Quote from BATS)

$5.18 USD

5.18
1,320,192

-0.34 (-6.16%)

Updated Nov 4, 2024 03:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Momentum Stocks to Buy for May 9th

by Zacks Equity Research

AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.

New Strong Buy Stocks for May 9th

by Zacks Equity Research

SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023

Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics (AQST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Aquestive Therapeutics (AQST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug

by Zacks Equity Research

RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease

Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.

    Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why

    by Zacks Equity Research

    Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.

    Verve (VERV) Up on Gene Editing Collaboration With Vertex

    by Zacks Equity Research

    Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.

      Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk

      by Zacks Equity Research

      Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.

      Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study

      by Zacks Equity Research

      Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.

      Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate

      by Zacks Equity Research

      Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.

      Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study

      by Zacks Equity Research

      Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.

      Intercept (ICPT) Reports Positive Data From NASH Study on OCA

      by Zacks Equity Research

      Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

      Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt

      by Zacks Equity Research

      Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.

      Roche's (RHHBY) Lunsumio Application Gets Priority Review

      by Zacks Equity Research

      Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.

      ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe

      by Zacks Equity Research

      ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.

      Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?